Blaine Davis - Jan 3, 2022 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Role
Chief Financial Officer
Signature
/s/ Jesse Shefferman, Attorney-in-Fact
Stock symbol
TARA
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 03:35 PM
Next filing
Jul 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARA Common Stock Award $0 +14.1K +952.06% $0.00 15.6K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARA Stock Option (Right to Buy) Award $0 +84.8K $0.00 84.8K Jan 3, 2022 Common Stock 84.8K $6.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 3, 2022.
F2 25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.